Elevance Health reported its fourth quarter and full year 2024 financial results, with adjusted earnings per share (EPS) of $3.84, matching analyst expectations. The company's operating revenue for the quarter reached $44.99 billion, slightly exceeding the forecast of $44.84 billion. However, medical membership figures fell short, totaling 45.7 million against an estimate of 46.22 million. For the full year 2025, Elevance Health projected adjusted EPS between $34.15 and $34.85, which is in line with the analyst estimate of $34.87. Following the earnings announcement, Elevance's stock rose by 5%, reflecting positive market sentiment despite the mixed results. The company also announced a 5% increase in its dividend to $1.71 per share, attributed to strong growth in its CarelonRx segment.